Shushan Hovsepyan: Highlights from the ARST1431 study about treatment outcomes of RMS patients

Shushan Hovsepyan shared a post on LinkedIn:

”How can we better use molecular insights to improve treatment outcomes of RMS patients?

Here are some highlights from the recent article discussing the results of the ARST1431 study in The Lancet. This is a randomized, open-label, phase 3 study by Children’s Oncology Group.”

Source: Shushan Hovsepyan/LinkedIn

Shushan Hovsepyan is a pediatric oncologist and adjunct assistant professor at the Yerevan State Medical University. Currently, she is the Editor-in-Chief of OncoDaily Medical Journal.

She completed her clinical fellowship at the National Institute of Cancer in Milan, Italy and at the St. Anna Children’s Research Hospital in Austria Furthermore, she held a research fellowship position at the European Organisation for Research and Treatment of Cancer in Brussels, Belgium.

Dr. Hovsepyan also completed the Postgraduate Harvard Medical School’s Effective Writing for Healthcare program. She is a former co-chair of the SIOP Global Health Network Education and Training Working Group.